Home › Furiex Pharmaceuticals Announces Positive Top-Line Results Of Two Pivotal Phase III Clinical Trials Of Eluxadoline In Patients With IBS-d
 

Keywords :   


Furiex Pharmaceuticals Announces Positive Top-Line Results Of Two Pivotal Phase III Clinical Trials Of Eluxadoline In Patients With IBS-d

2014-02-05 07:38:22| drugdiscoveryonline Home Page

Furiex Pharmaceuticals, Inc. recently announced top-line results indicating the company’s two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain

Tags: with results iii positive

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 9
05.11Tropical Storm Rafael Wind Speed Probabilities Number 9
05.11Tropical Storm Rafael Public Advisory Number 9
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 9
05.11Kim Madigan to chair 2025 FTA Fall Technical Conference
05.11PM responds to Sir Alan Bates after repeated requests
More »